This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2013 Sep;146(5):245-6.

doi: 10.1177/1715163513499127.

Addressing the authorization of orphan drugs will not fix reimbursement problems: The elephant is still in the room

Affiliations

PMID: 24093029
PMCID: PMC3785191
DOI: 10.1177/1715163513499127

Addressing the authorization of orphan drugs will not fix reimbursement problems: The elephant is still in the room

Mark Embrett. Can Pharm J (Ott). 2013 Sep.

. 2013 Sep;146(5):245-6.

doi: 10.1177/1715163513499127.

Author

Affiliation

¹ Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario.

PMID: 24093029
PMCID: PMC3785191
DOI: 10.1177/1715163513499127

No abstract available

PubMed Disclaimer

Similar articles

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP, Kawalec P, Trabka W, Sowada C, Pilc A. Malinowski KP, et al. Front Pharmacol. 2018 Nov 12;9:1263. doi: 10.3389/fphar.2018.01263. eCollection 2018. Front Pharmacol. 2018. PMID: 30483124 Free PMC article.
[Authorization and reimbursement of orphan drugs in an international comparison].
Roll K, Stargardt T, Schreyögg J. Roll K, et al. Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16. Gesundheitswesen. 2011. PMID: 20848380 Review. German.
Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A, Mergaert L, Fostier C, Cleemput I, Hulstaert F, Simoens S. Denis A, et al. Pharmacoeconomics. 2011 Oct;29(10):883-93. doi: 10.2165/11585980-000000000-00000. Pharmacoeconomics. 2011. PMID: 21905759
Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
Blankart CR, Stargardt T, Schreyögg J. Blankart CR, et al. Pharmacoeconomics. 2011 Jan;29(1):63-82. doi: 10.2165/11539190-000000000-00000. Pharmacoeconomics. 2011. PMID: 21073206
[Orphan diseases and orphan medicines: a Belgian and European study].
Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Denis A, et al. J Pharm Belg. 2009 Dec;(4):131-7. J Pharm Belg. 2009. PMID: 20183989 Review. French.

See all similar articles

Cited by

Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?
Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Potter BK, et al. Genet Med. 2016 Feb;18(2):117-23. doi: 10.1038/gim.2015.42. Epub 2015 Apr 9. Genet Med. 2016. PMID: 25856667 Review.

References

1. Romanow R. Building on values: the future of health care in Canada. 2002. Available: http://publications.gc.ca/collections/Collection/CP32-85-2002E.pdf (accessed July 4, 2013).
1. Kirby M, LeBreton M. The health of Canadians: the federal role, 2002. Available: www.parl.gc.ca/37/2/parlbus/commbus/senate/Com-e/soci-e/rep-e/repoct02vo... (accessed July 4, 2013).
1. MacKinnon N, Ip I. The national pharmaceuticals strategy: rest in peace, revive, or renew? CMAJ 2009;180:801-3 - PMC - PubMed
1. Embrett M, MacKinnon N. Qualitative evaluation of the Canadian Fabry Disease Initiative. Can Pharm J (Ott) 2012;145:136-41 - PMC - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations